Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

by Martínez, E, Arranz, JA, Podzamczer, D, Lonca, M, Sanz, J, Barragán, P, Knobel, H, Ribera, E, Gutierrez, F, Valero, S, Clotet, B, Dalmau, D, Segura, F, Arribas, JR, Barrufet, P, Santos, I, Payeras, A, de Lazzari, E, Pich, J, Gatell, J
Published 2010